- Home
- HL vs EXEL Comparison
HL vs EXEL Comparison
Compare HL & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HL
- EXEL
- Stock Information
- Founded
- HL 1891
- EXEL 1994
- Country
- HL United States
- EXEL United States
- Employees
- HL N/A
- EXEL N/A
- Industry
- HL Precious Metals
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HL Basic Materials
- EXEL Health Care
- Exchange
- HL Nasdaq
- EXEL Nasdaq
- Market Cap
- HL 9.4B
- EXEL 11.1B
- IPO Year
- HL N/A
- EXEL 2000
- Fundamental
- Price
- HL $13.29
- EXEL $41.88
- Analyst Decision
- HL Buy
- EXEL Buy
- Analyst Count
- HL 7
- EXEL 24
- Target Price
- HL $10.93
- EXEL $44.73
- AVG Volume (30 Days)
- HL 17.3M
- EXEL 2.7M
- Earning Date
- HL 11-05-2025
- EXEL 11-04-2025
- Dividend Yield
- HL 0.11%
- EXEL N/A
- EPS Growth
- HL N/A
- EXEL 53.55
- EPS
- HL 0.31
- EXEL 2.38
- Revenue
- HL $1,224,563,000.00
- EXEL $2,288,218,000.00
- Revenue This Year
- HL $16.78
- EXEL $9.14
- Revenue Next Year
- HL $2.30
- EXEL $12.51
- P/E Ratio
- HL $42.67
- EXEL $17.58
- Revenue Growth
- HL 45.62
- EXEL 9.93
- 52 Week Low
- HL $4.46
- EXEL $31.90
- 52 Week High
- HL $16.10
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- HL 48.35
- EXEL 56.12
- Support Level
- HL $13.67
- EXEL $41.65
- Resistance Level
- HL $14.85
- EXEL $42.99
- Average True Range (ATR)
- HL 1.00
- EXEL 1.52
- MACD
- HL -0.10
- EXEL 0.13
- Stochastic Oscillator
- HL 33.72
- EXEL 75.26
About HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.